Takeda Pharmaceutical Company Limited
Nitrogen-containing heterocyclic compound

Last updated:

Abstract:

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. ##STR00001## wherein each symbol is as described in the specification, or a salt thereof.

Status:
Grant
Type:

Utility

Filling date:

4 Dec 2018

Issue date:

15 Dec 2020